
    
      -  To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose
           (MTD) of AS1409 in single and repeated doses.

        -  To determine biological responses to AS1409, including interferon-Î³ and IP-10
           circulating concentrations.

        -  To determine preliminary pharmacokinetics of AS1409.

        -  To determine the immunogenicity of AS1409

        -  To explore the anti-tumour activity of AS1409.
    
  